This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 i…

HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more

~Estimated

~$10 – $8,750

Iambic Therapeutics, IncNCT06253871

Phase 1

A Phase I Dose Escalation Trial of Compartmental Radioimmunotherapy (cRIT) Using 177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory B7H3 Expressing Primary or Metastatic CNS Tumors

The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblasto…

Recurrent MedulloblastomaRefractory MedulloblastomaCNS Metastases+1 more

~Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07698899